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Abbreviations: 8-O-dG, 8-oxo-7, 8-dihydroguanine; ATG, autophagy-related; BECN1, Beclin 1, autophagy-related; BSA, bovine serum
albumin; CASP3, caspase 3; CD24, cluster of differentiation 24; DAPI, 40, 6-diamidino-2-phenylindole; DFS, disease-free
survival; DMEM, Dulbecco’s modified Eagle’s medium; E, 17b-estradiol; EGF, epidermal growth factor; EGFP, enhanced green fluores-
cent protein; EGFR/ERBB1, epidermal growth factor receptor; EM, electron microscopy; EMT, epithelial-to-mesenchymal transition;
ESR1, estrogen receptor 1; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; FACS, fluorescence activated cell
sorting; FGF2/bFGF, fibroblast growth factor 2 (basic); GSEA, gene set enrichment analysis; H&E, hematoxylin & eosin; HR, hormone
receptor; IF, immunofluorescence; IHC, immunohistochemistry; IL, interleukin; iMMECs, immortalized mouse mammary epithelial
cells; ITGB1/CD29, Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12); ITGB3/CD61,
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61); KRT, keratin; LIN¡, lineage negative (CD31¡ CD45¡ LY76¡);
MAP1LC3B/LC3B, microtubule-associated protein 1 light chain 3 beta; MaPC, mammary progenitor cell; MaSC, mammary stem cell;
MEC, mammary epithelial cell; MEGM, mammary epithelial growth medium; MGs, mammary glands; MKI67, marker of proliferation
Ki-67; MMTV, mouse mammary tumor virus; NFKB/NFkB, nuclear factor of kappa light polypeptide gene enhancer in B-cells; p-
KRT8/p-K8, phosphorylated Keratin 8; PBS, phosphate-buffered saline; PECAM1/CD31, platelet/endothelial cell adhesion molecule 1;
PI, propidium iodide; PGR, progesterone receptor; PTPRC/CD45, protein tyrosine phosphatase, receptor type, C; RELA/P65, v-rel
avian reticuloendotheliosis viral oncogene homolog a; ROS, reactive oxygen species; SD, standard deviation; SNPs, single nucleotide
polymorphisms; SQSTM1/p62, sequestosome1; TEBs, terminal end buds; LY76/TER119, lymphocyte antigen 76; TNBCs, triple-nega-
tive breast cancers; TNF, tumor necrosis factor; TNFRSF11A/TNR11/RANK, tumor necrosis factor receptor superfamily, member 11a,
NFKB activator; TNFSF11/TNF11/RANKL, tumor necrosis factor (ligand) superfamily, member 11; TP53 (TRP53 in mice), tumor
protein p53 (transformation related protein 53 in mice); WNT1, wingless-Type MMTV integration site family, member 1.
Earlier studies reported allelic deletion of the essential autophagy regulator BECN1 in breast cancers implicating BECN1
loss, and likely defective autophagy, in tumorigenesis. Recent studies have questioned the tumor suppressive role of
autophagy, as autophagy-related gene (Atg) defects generally suppress tumorigenesis in well-characterized mouse
tumor models. We now report that, while it delays or does not alter mammary tumorigenesis driven by Palb2 loss or
ERBB2 and PyMT overexpression, monoallelic Becn1 loss promotes mammary tumor development in 2 speciﬁc contexts,
namely following parity and in association with wingless-type MMTV integration site family, member 1 (WNT1) activation.
Our studies demonstrate that Becn1 heterozygosity, which results in immature mammary epithelial cell expansion and
aberrant TNFRSF11A/TNR11/RANK (tumor necrosis factor receptor superfamily, member 11a, NFKB activator) signaling,
promotes mammary tumorigenesis in multiparous FVB/N mice and in cooperation with the progenitor cell-transforming
WNT1 oncogene. Similar to our Becn1C/¡;MMTV-Wnt1 mouse model, low BECN1 expression and an activated WNT
pathway gene signature correlate with the triple-negative subtype, TNFRSF11A axis activation and poor prognosis in
human breast cancers. Our results suggest that BECN1 may have nonautophagy-related roles in mammary development,
provide insight in the seemingly paradoxical roles of BECN1 in tumorigenesis, and constitute the basis for further studies
on the pathophysiology and treatment of clinically aggressive triple negative breast cancers (TNBCs).
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Introduction
Macroautophagy (hereforth referred to as autophagy) is a cata-
bolic process whereby protein aggregates and damaged organelles are
constitutively degraded in lysosomes.1 Cells also activate autophagy
to survive under stress by recycling cytoplasmic material for energy
production and biomolecular synthesis.1 Defective autophagy was
first implicated in tumorigenesis with the report that the essential
autophagy regulator BECN1/Beclin1 is allelically deleted in human
cancers, including breast cancer,2 restoration of BECN1 expression
in MCF7 breast carcinoma cells compromises xenograft tumor
growth,3 andBecn1C/¡mice develop spontaneous lung and liver car-
cinomas, lymphomas, and mammary hyperplasias.4,5 Furthermore,
apoptosis-defective Becn1C/¡ immortalized mouse mammary epi-
thelial cells (iMMECs) aremore tumorigenic in nudemice, accumu-
late DNA damage and are more genomically unstable than their
wild-type counterparts.6 Recently, work from Rosenfeldt and col-
leagues eloquently describes synergy between defective autophagy
and tumor protein 53 (TP53/Trp53/p53, note that the mouse
nomenclature is Trp53, but we use the TP53 acronym hereafter to
refer to both the human and mouse genes/proteins for simplicity)
loss in KRAS (Kirsten rat sarcoma viral oncogene homolog)-driven
pancreatic cancer,7 while studies investigating the role of functional
autophagy in ERBB2 (v-erb-b2 avian erythoblastic leukemia viral
oncogene homolog 2)-positive and EGFR/ERBB1 (epidermal
growth factor receptor)-expressing cells also implicate autophagy
suppression in cell transformation driven by these oncogenes in
mammary8 and lung9 epithelium, respectively.
Seemingly contradicting the results described above, several stud-
ies have reported that functional autophagy is required for tumori-
genesis and tumor progression in some contexts.7,10-14 Recent
publications shed light on the role of BECN1, and autophagy in gen-
eral, in mammary physiology, as ATG proteins have been found
important for breast cancer stem cell maintenance10 and dead cell
clearance in mammary involution.15 The role of BECN1 in mam-
mary tumorigenesis is likely complex, as mammary glands (MGs)
from Becn1C/¡ mice exhibit increased proliferation in puberty and
hyperplasias with age, but no mammary tumors.4 Furthermore,
monoallelic Becn1 loss does not have an impact on ERBB2- or
PyMT-driven mammary tumorigenesis,8 whereas it delays tumor
formation due to mammary gland-specific biallelic Palb2 deletion in
a wild-type Tp53 background.13 The tumor-suppressive role of
BECN1 in tumorigenesis has also recently been challenged by the
finding that in human breast and ovarian cancers, large genomic dele-
tions encompassing both BRCA1 and BECN1, and deletions of only
BRCA1 but not BECN1, are observed.16
Our earlier study demonstrates that phosphorylated keratin 8
(p-KRT8) accumulates in autophagy-deficient iMMECs, tissues,
and tumors, implicating autophagy in keratin homeostasis.17
Building on this work, we now report that Becn1C/¡, compared
with Becn1C/C, iMMECs and iMMEC-generated tumors also
exhibited KRT6 (keratin 6) upregulation. KRT6 is not only a
basal cell marker in skin and mammary tissue, but also a marker
for bipotent mammary progenitor cells and for cells with
increased tumorigenic potential.18,19 We also report that KRT6-
positive cells, likely representing bipotent mammary progenitor
cells, are aberrantly present in MGs from postpubertal Becn1C/¡
mice. Furthermore, we demonstrate that monoallelic Becn1 loss
results in augmented mammary stem and progenitor cell activi-
ties and TNFRSF11A-NFKB axis upregulation; it also promotes
mammary tumor development following parity and accelerates
WNT1-driven mammary tumorigenesis, which itself involves
progenitor cell transformation.18,20 Thus, our studies elucidate 2
physiologically relevant contexts in which monoallelic Becn1 loss
promotes mammary tumorigenesis, giving rise to tumors with
basal-like characteristics.
Results
Monoallelic Becn1 loss results in KRT6 upregulation in
mammary epithelial cells and tissues
Apoptosis-defective Becn1C/¡ iMMECs have previously been
reported to be more tumorigenic in nude mice than their
Becn1C/C counterparts.6 To investigate Becn1 genotype-specific
differences in iMMECs and iMMEC-generated mammary
tumors in nude mice, we performed gene expression analysis,
which revealed that KRT6 was upregulated in Becn1C/¡
iMMECs (Fig. 1A and B) and, to an even higher and significant
degree, in Becn1C/¡ iMMEC-generated allograft tumors (Fig. 1A
and C). These tumors also displayed increased KRT14 expression
compared with tumors resulting from orthotopic implantation of
Becn1C/C iMMECs (Fig. 1C), further indicating an association
between monoallelic Becn1 loss and basal keratin expression in
mammary tumor cells. This finding is in agreement with our
recently published study, which reports that low BECN1 mRNA
levels correlate with the basal-like and ERBB2, but not luminal,
breast cancer subtypes.8
To exclude the possibility that KRT6 upregulation in Becn1C/¡
iMMECs and iMMEC-generated tumors resulted from the pro-
cess of mammary epithelial cell (MEC) immortalization,6 we
investigated KRT6 expression in MGs from Becn1C/C and
Becn1C/¡ mice. As previously reported,21 KRT6 was detected in
MGs from pubertal wild-type mice, whereas hardly any KRT6-
positive cells were seen in MGs from aged wild-type mice
(Fig. 1D). Mammary epithelium from pubertal Becn1C/¡ mice
exhibited uniformly robust KRT6 expression, whereas KRT6-pos-
itive, not costaining with the luminal cytokeratin KRT8, cells were
observed in MGs from aged Becn1C/¡mice (Fig. 1D).
Since bipotent mammary progenitor cells express KRT6,19 we
examined whether KRT6-positive cells observed in MGs from
older Becn1C/¡ mice also expressed mammary stem cell (MaSC)
and progenitor cell markers.22,23 We indeed found that these
cells costained with the MaSC and progenitor cell marker CD24
(cluster differentiation 24) and expressed low levels of the MaSC
marker CD29/integrin-b1 (cluster differentiation 29) (Fig. 1E),
thus suggesting that monoallelic Becn1 loss leads to accumulation
of KRT6-positive bipotent mammary progenitor cells.
Monoallelic Becn1 loss results in accelerated mammary fat
pad filling and excessive ductal side-branching
In agreement with earlier results using a different Becn1C/¡
transgenic line,4 we also detected increased proliferation in
www.landesbioscience.com 2037Autophagy
mammary ducts and terminal end buds
(TEBs) from 5-wk-old Becn1C/¡ mice5 (Fig.
S1A and S1B); apoptosis rates were similar
(Fig. S1C and S1D). Consistent with the
partially defective autophagic response
observed in Becn1C/¡ iMMECs under meta-
bolic stress,6 lower levels of MAP1LC3B/
LC3B (microtubule-associated protein 1
light chain 3 b) and accumulation of
SQSTM1/p62 (sequestosome 1) were
observed in MGs from Becn1C/¡ mice
(Fig. S1E and S1F).
Systematic examination of MGs from
cohoused Becn1C/C and Becn1C/¡ littermates
revealed that 6.5-wk-old Becn1C/¡ mice
exhibited accelerated mammary fat-pad fill-
ing and increased ductal side-branching
(Fig. 2A and B). The latter phenotype per-
sisted and was further accentuated in MGs
from 6-mo-old nulliparous Becn1C/¡ mice
(Fig. 2C, upper panel); at that age, Becn1C/¡
mice also exhibited mammary hyperplasias
(Fig. 2C, lower panel). The difference in
ductal side-branching in MGs from
Becn1C/C and Becn1C/¡ mice became less
pronounced by 12 mo of age (Fig. 2D), pos-
sibly indicating that increased ductal side-
branching may be a hormonally regulated
phenotype.
Monoallelic Becn1 loss results in
functionally enriched mammary stem and
progenitor cell populations
Faster mammary fat pad filling and exces-
sive ductal side-branching result from
increased mammary stem and progenitor cell
populations/activity, respectively.22 We uti-
lized fluorescence-activated cell sorting
(FACS) to isolate PI¡ LIN¡ CD24C
CD29hi, i.e. mammary stem cell (MaSC)-
containing, and PI¡ LIN¡ CD24C CD29lo,
i.e. mammary progenitor cell (MaPC)-con-
taining, populations22 from cohoused
Becn1C/C and Becn1C/¡ littermates.
Although the relative proportions of MaSC-, MaPC-, and CD61
(cluster differentiation 61)C luminal progenitor cell-containing
populations22-24 were similar between the 2 genotypes (Fig. S2A
and S2B), MGs from Becn1C/¡ mice consistently demonstrated
higher MaSC and MaPC activities by in vitro and in vivo func-
tional assays (Fig. 3; Fig. S2C and S2D). Specifically, CD24C
CD29hi Becn1C/¡ MECs exhibited increased MaSC activity, as
measured by primary and limiting dilution mammosphere
(Fig. 3A, left and right panel, respectively) and 3D colony-for-
mation (Fig. 3B) assays.23,25 Furthermore, CD24C CD29lo
Becn1C/¡MECs exhibited increased MaPC activity (Fig. 3C), as
measured by number of colonies formed in 2D-matrigel
assays.23,25
The in vivo stem/progenitor cell activity of CD24C CD29hi
Becn1C/C and Becn1C/¡ MECs was evaluated by contralateral
transplantation of these cells into cleared 4th mammary fat pads
of wild-type mice.22 CD24C CD29hi Becn1C/¡ MECs consis-
tently resulted in higher number of successful (i.e. giving rise to
mammary outgrowths) transplantations (Fig. 3D; Fig. S2C and
S2D). Six weeks post-transplantation, comparison of similarly
filled fat pads revealed that CD24C CD29hi Becn1C/¡ MECs
gave rise to outgrowths with more extensive side-branching than
Figure 1. Monoallelic Becn1 loss results in KRT6 upregulation in mammary epithelial cells and
tissues. (A) Microarray analysis was performed on samples (three each) of Becn1C/C and Becn1C/
¡ apoptosis-competent and apoptosis-defective iMMECS, as well as mammary tumors derived
from orthotopic implantation of apoptosis-defective iMMECs in nude mice. KRT6 expression
relative to that in apoptosis-competent Becn1C/C iMMECs is presented as means§ SDs (n D 3).
(B–D) Becn1C/C (left) and Becn1C/¡ (right) with DAPI (blue) by IF: (B) More KRT6-expressing cells
are seen in Becn1C/¡ apoptosis-competent iMMECs (top) and Becn1C/¡ apoptosis-defective
iMMECs (bottom) under normal growth conditions. (C) More KRT6-expressing (green, top) and
KRT14-expressing (red, bottom) cells are seen in allograft mammary tumors generated by
Becn1C/¡ apoptosis-defective iMMECs. (D) MGs from 5-wk-old (top) and 9-mo-old (bottom)
Becn1C/¡mice reveals increased number of KRT6-positive (green) cells that are not KRT8-positive
(red). (E) Costaining for KRT6 (purple), CD24 (red), CD29 (green) in MGs from 9-mo-old Becn1C/¡
mice reveals that KRT6-positve cells colocalize with mammary progenitor cell markers. Scale bar:
(B and D) 30 mm; (C and E) 37.5 mm.
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CD24C CD29hi Becn1C/CMECs (Fig. 3E). This phenotype was
similar to that observed in MGs from Becn1C/¡ mice (Fig. 2),
suggesting that transplantation of MaSC-containing Becn1C/¡
MECs in wild-type mice sufficiently reproduced the side-branch-
ing phenotype observed in native MGs from Becn1C/¡ mice,
where all cell types (MECs and stroma) are missing one Becn1
allele.
Since transplantations of CD24C CD29hi Becn1C/C and
Becn1C/¡ MECs were performed in wild-type recipient mice, we
examined the autophagy status of resulting outgrowths and found
that similar to MGs from Becn1C/¡ mice
(Fig. S1E and S1F), CD24C CD29hi
Becn1C/¡MEC-generated outgrowths exhib-
ited LC3B expression decrease and SQSTM1
accumulation (Fig. S2E and S2F). Further-
more, similar to MGs from Becn1C/¡ mice
(Fig. S1A and S1B), proliferation rates in
TEBs and mammary ducts were significantly
higher in outgrowths derived from CD24C
CD29hi Becn1C/¡ MEC transplantation
(Fig. 4A and B). In contrast to similar apo-
ptosis rates observed in native glands (Fig.
S1C and S1D), in CD24C CD29hi Becn1C/¡
MEC-generated outgrowths, apoptosis was
suppressed (Fig. 4C and D), possibly due to
enrichment in more apoptosis-resistant
MaSCs andMaPCs.
MEC subpopulations exhibit different
levels of autophagic activity
Given that monoallelic Becn1 loss
resulted in deregulation of the mammary
hierarchy, thus implicating BECN1, and
possibly autophagy in general, in mammary
differentiation, we isolated MEC popula-
tions from wild-type mice, as described
above, and examined basal autophagy in
these populations by electron microscopy
(EM)17 (Fig. S3). The CD24C CD29hi pop-
ulation exhibited paucity in mitochondria,
autophagosomes, and other cytoplasmic
organelles (Fig. S3, left panel), whereas the
CD24C CD29lo population showed high
autophagic activity, as illustrated by the pres-
ence of numerous autophagosomes (Fig. S3,
middle panel). Interestingly, the autophago-
somal cargo was different between CD24C
CD29hi and CD24C CD29lo MECs; in the
former (MaSC-containing) population,
autophagosomes appeared largely carrying
mitochondria, while in the latter (progenitor
cell-containing) population, diverse cargo
was observed in autophagosomes. Lastly,
CD24¡ MECs contained fewer autophago-
somes than the CD24C CD29lo population,
but more than the CD24C CD29hi com-
partment, and more mitochondria than both other MEC popula-
tions examined (Fig. S3, right panel). High autophagy induction
in CD24C CD29lo MECs, though not a proof, suggests that
autophagy may play a significant role in mammary differentia-
tion, which is also accompanied by enrichment in mitochondria.
Krt14-driven biallelic Atg7 deletion delays mammary fat pad
filling, without altering ductal side-branching
In an effort to investigate whether the increased ductal side-
branching and enriched MaSC and progenitor cell activities
Figure 2. Monoallelic Becn1 loss results in accelerated mammary fat pad ﬁlling and excessive
ductal side-branching. (A–D) Analysis of mouse mammary epithelium from Becn1C/C (left) and
Becn1C/¡ (right) mice (n D 3 to 5): (A) MG whole mounts from 6.5-wk-old mice, with circle identi-
fying an unﬁlled (left) vs. ﬁlled (right) fat pad and (B) (top) quantiﬁcation of number of side-
branches per primary branch per ﬁeld and (bottom) quantiﬁcation of percentage of mammary
fat pad 4 ﬁlled with epithelium. Three MG specimen per genotype from cohoused Becn1C/C and
Becn1C/¡ littermates were evaluated. Results are presented as means § SDs. (C) MG whole
mounts (top) and hematoxylin and eosin staining of MG sections (bottom) from 6-mo-old mice,
with mammary hyperplasia in separate insert. (D) MG whole mounts from 12-mo-old mice. Scale
bar: (A, C,and D) 5 mm for whole mounts; (A, C, and D) 2 mm for whole mount enlargements.
Scale bar: (C) 100 mm for H&Es; 200 mm for hyperplasia. *P< 0.05 by a 2-tailed Student t test.
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observed in MGs from Becn1C/¡ mice were
secondary to defective autophagy associated
with monoallelic Becn1 loss or to a nonau-
tophagy-related BECN1 function, we gener-
ated mice with conditional biallelic deletion
of the essential autophagy regulator Atg726
utilizing Krt14 promoter-driven expression of
CRE recombinase.27 In agreement with prior
studies showing that Atg7 is not happloinsuf-
ficient for autophagy deficiency or other phe-
notypes,26 we found that MGs from Atg7C/C
and Atg7F/C;Krt14-Cre mice displayed similar
morphological characteristics (data not
shown).
In MGs from atg7F/F;Krt14-Cre mice,
Atg7 deletion and defective autophagy sta-
tus were confirmed (Fig. S4A and S4B). In
contrast to our observations in developing
MGs from Becn1C/¡ mice (Fig. 2A and B),
whole MG mounts revealed no difference
in ductal side-branching between Atg7C/C
and atg7F/F;Krt14-Cre mice and, more
impressively, showed delayed—rather than
accelerated—fat pad filling in 6.5-wk-old
atg7F/F;Krt14-Cre mice (Fig. S4C and
S4D). While proliferation rates were simi-
lar, increased apoptosis was detected in
MGs from atg7F/F;Krt14-Cre compared
with Atg7C/C mice (Fig. S4E and S4F).
Furthermore, KRT6, KRT8, and KRT14
levels were comparable in MGs from atg7F/
F;Krt14-Cre and Atg7C/C mice (Fig. S4G
and S4H). Although functional in vitro
and in vivo studies for MaSC and progeni-
tor cell activities in Atg7C/C and Atg7-null
CD24C CD29hi and CD24C CD29lo
MECs were not performed, decreased
mammary fat pad filling in pubertal MGs
from atg7F/F;Krt14-Cre mice suggests, at
least partial, impairment of MaSC or pro-
genitor cell function in association with
MEC-specific biallelic Atg7 deletion, and
points to a nonautophagy-related role of
BECN1 in mammary differentiation. Alter-
natively, and together with the evidence for
high autophagic activity during mammary
epithelial differentiation (Fig. S3) and the
mammary phenotypes observed in MGs
from Becn1C/¡ mice (Figs. 1, 2, and 3), it
raises the possibility of a dose-dependent
requirement for functional autophagy in
MaSC and progenitor cell maintenance. If
this is the case, partial autophagy deficiency may affect mam-
mary cell hierarchy differently than a more severe autophagy
defect. Further investigation of these 2 not necessarily mutu-
ally exclusive, mechanistic possibilities will be needed.
Monoallelic Becn1 loss results in TNFRSF11A-NFKB
pathway activation in mammary tissues
TNFSF11/TNF11/RANKL (tumor necrosis factor [ligand]
superfamily, member 11) has been implicated in progesterone-
Figure 3.Monoallelic Becn1 loss results in functionally enriched mammary stem and progenitor
cell populations. (A–C) Freshly isolated Becn1C/C (blue) and Becn1C/¡ (red) MECs were used,
experiments were performed 3 independent times and outcomes are presented as means §
SDs. (A) Primary mammosphere assays performed using Pi¡ LIN(CD31,CD45,LY76)¡ CD24C
CD29hi MECs plated at 20,000 cells per well (left) and in limiting dilution of 500 to 25 CD24C
CD29hi MECs plated (right) reveal increased MaSC activity in Becn1C/¡ MECs. (B) 3D colony-for-
mation by CD24C CD29hi Becn1C/¡ compared with Becn1C/C MECs plated at 20,000 cells per
well shows increased MaSC activity. (C) Colony formation by CD24C CD29lo Becn1C/¡ compared
with Becn1C/C MECs plated at 1,000 cells per well reveals increased colony forming ability in
2D-matrigel conditions. (D) Increased repopulation frequency and mammary fat pad ﬁlling are
seen following transplantation of 250 CD24C CD29hi Becn1C/¡ MECs isolated from 5-wk-old
mice. Becn1C/C (left) and Becn1C/¡ (right), contralateral transplantations in wild-type recipient
mouse. Circles represent fat pads and the black color represents the percentage of the mam-
mary fat pad that is ﬁlled in. (E) Representative whole mount images of outgrowths from con-
tralateral CD24C CD29hi Becn1C/C and Becn1C/¡ MEC transplantation are shown and reveal
increased ductal side branching in Becn1C/¡ samples. *P < 0.05 by a 2-tailed Student t test.
Scale bar: (E) 5 mm for whole mounts; 2 mm for whole mount enlargements.
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induced MaSC expansion28 and mice overexpressing TNFSF11
or its receptor, TNFRSF11A/RANK (tumor necrosis factor
receptor superfamily, member 11a, NFKB activator), under the
mouse mammary tumor virus (MMTV) promoter,29,30 exhibit
mammary phenotypes similar to Becn1C/¡ mice, including exces-
sive ductal side-branching (Fig. 2), increased proliferation (Fig.
S1A and S1B), and mammary hyperplasias (Fig. 2C), but no
mammary tumors in nulliparous mice.4,15 We hypothesized that
ectopic TNFRSF11A-TNFSF11 signaling may be mediating the
increased mammary stem and progenitor cell activities in MGs
from Becn1C/¡ mice. TNFSF11 was indeed detected in MGs
from pubertal Becn1C/¡ mice (Fig. 4E) and robustly in out-
growths from CD24C CD29hi Becn1C/¡ MEC transplantations
(Fig. 4F). Consistent with aberrant
TNFRSF11A pathway activation, out-
growths from CD24C CD29hi Becn1C/¡
MEC transplantation also displayed
increased TNFRSF11A expression
(Fig. 4F) and likely activation of the down-
stream effector NFKB axis,31 as indicated
by increased expression, though not appar-
ent nuclear localization, of RELA (Fig. 4F).
In agreement with previous studies,28-30,32-
34 this data suggests that aberrant
TNFRSF11A pathway activation may play
a role in the MaSC and progenitor cell
expansion observed in association with
monoallelic Becn1 loss. However, further
studies will need to be conducted to deter-
mine whether TNFRSF11A signaling is
responsible for the mammary phenotypes
observed in Becn1C/¡ mice.
Locally increased progesterone signaling
in MGs from Becn1C/¡mice
Given that progesterone is required for
mammary ductal side-branching35 and
TNFSF11 is a mediator of both progester-
one signaling28,32 and progestin-induced
mammary tumorigenesis,34 we examined
MGs from cohoused Becn1C/C and
Becn1C/¡ littermate mice for evidence of
progesterone signaling. As shown (Fig. 5A
and B), monoallelic Becn1 loss resulted in
higher proportion of PGR (progesterone
receptor)-positive MECs. Transplantation
of CD24C CD29hi Becn1C/C and Becn1C/¡
MECs into contralateral fat pads of a wild-
type recipient resulted in mammary out-
growths of both Becn1 genotypes in the
same mouse; similar to native MGs, and
despite uniform systemic hormone levels,
the proportion of nuclear PGR-positive
cells was again higher in outgrowths gener-
ated by Becn1C/¡ MECs (Fig. 5C and D),
indicating that monoallelic Becn1 loss
results in locally-regulated increased progesterone signaling.
To investigate the role of hormonal signaling in the mammary
hyper side-branching phenotype observed in association with
monoallelic Becn1 loss, Becn1C/C and Becn1C/¡ mice were ovari-
ectomized at 3 to 4 wk of age. In the absence of endogenous hor-
mone production, MGs from Becn1C/C and Becn1C/¡ mice
displayed similar ductal side-branching (Fig. 5E), whereas hor-
monal stimulation of ovariectomized mice with exogenous 17b-
estradiol and progesterone32 rescued the hyper ductal side-
branching phenotype in Becn1C/¡ vs. Becn1C/C mice (Fig. 5E).
This data implies that hormonal signaling is required for the
increased ductal side-branching seen in MGs from Becn1C/¡
mice, and supports our observations that this phenotype is
Figure 4. Outgrowths from CD24C CD29hi Becn1C/¡ MEC transplantation display increased prolif-
eration and TNFSF-NFKB pathway activation. (A–D, and F) Examination of outgrowths from con-
tralateral transplantations of CD24C CD29hi Becn1C/C and Becn1C/¡ MECs, and (E) native MGs
from 6.5-wk-old cohoused Becn1C/C and Becn1C/¡ littermates. (A) Representative images show
more MKI67C cells in ducts (top) and TEBs (bottom) of outgrowths from CD24C CD29hi Becn1C/¡
MEC transplantation; (B) quantiﬁcation of MKI67C cells in mammary ducts and TEBs is shown as
means§ SDs (n D 3 mammary gland specimens per genotype). (C) Representative images show
fewer cleaved CASP3-staining cells in ducts (top) and TEBs (bottom) of outgrowths from CD24C
CD29hi Becn1C/¡ MEC transplantation; (D) quantiﬁcation of cleaved CASP3C cells in mammary
ducts and TEBs is shown as means § SDs (n D 3 mammary gland specimens per genotype).
Increased TNFSF11 (red) expression is seen in (E) native MGs from 6.5-wk-old Becn1C/¡ mice and
(F) outgrowths from contralateral CD24C CD29hi Becn1C/¡ MEC transplantation (top panel).
Increased TNFRSF11A (middle panel) and RELA (bottom panel) levels are also seen in outgrowths
from CD24C CD29hi Becn1C/¡ MEC transplantation. Scale bar: (A, C, E, and F, middle and bottom
panels) 30 mm ; (F, top panel) 40 mm.
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associated with progesterone axis activation (Fig. 2C and D) and
is likely hormonally regulated.
In progesterone-
driven TNFRSF11A sig-
naling, exogenous pro-
gesterone activates
PGR-positive MECs to
secrete TNFSF11,
which in turn induces
proliferation of neigh-
boring TNFRSF11A-
expressing mammary
stem and progenitor
cells and subsequent
generation of more
PGR-positive MECs,
thus creating a positive
feedback loop.28,32 In
macrophages, TNFSF11
production and activa-
tion of TNFRSF11A-
NFKB signaling is
driven by proinflamma-
tory cytokines.36 In our
studies, where contralat-
erally transplanted
Becn1C/C and Becn1C/¡
MECs are exposed to
the same systemic hor-
mones, outgrowths gen-
erated by CD24C
CD29hi Becn1C/¡
MECs displayed
increased IL1B (inter-
leukin 1, b) and TNF/
TNFa (tumor necrosis
factor) levels (Fig. 5F),
which were not accom-
panied by enhanced
macrophage infiltration
(Fig. 5G). Together
these studies indicate
that IL1B and TNF
were likely secreted by
and acting autono-
mously on Becn1C/¡
MECs.
Autophagy-deficient
tissues commonly har-
bor a proinflammatory
microenvironment,37
mainly attributed to
increased reactive oxy-
gen species (ROS) due
to impaired removal of
damaged mitochon-
dria.37 Consistent with their functional autophagy defect (Fig.
S2E and S2F), CD24C CD29hi Becn1C/¡ MEC-generated
Figure 5. Augmented progesterone signaling, cytokines, and oxidative stress detected upon monoallelic Becn1 loss.
(A and C) Nuclear PGR (red) and KRT6 (green) cell staining in native MGs from cohoused Becn1C/C and Becn1C/¡ MEC
and outgrowths from contralateral CD24C CD29hi Becn1C/C and Becn1C/¡ MEC transplantation. (A) Representative
images of PGRC and KRT6C cells and (B) quantiﬁcation of nuclear PGRC cells (left) and KRT6C cells (right) in MGs from 5-
wk old mice reveals increased numbers of PGRC and KRT6C cells in Becn1C/¡mice. (C) Representative images of nuclear
PGRC cells (top panel) and KRT6C cells (bottom panel) in outgrowths from contralateral CD24C CD29hi Becn1C/C and
Becn1C/¡ MEC transplantation with (D) quantiﬁcation of PGRC cells (top panel) and KRT6C cells (bottom panel). Results
are presented as means § SDs (n D 3 mammary gland specimens per genotype). (E) Quantiﬁcation of ductal side-
branching in MGs from hormonally stimulated following ovariectomization, where Sham D ovariectomized, Vehicle D
ovariectomized C 100 mL sesame oil daily, and E C P D ovariectomized C 5 mg 17B-estradiol C 5 mg progesterone in
100 mL of sesame oil daily. (F–H) Examination of outgrowths from contralateral transplantations of CD24C CD29hi
Becn1C/C and Becn1C/¡ MECs. (F) Increased IL1B (top panel) and TNF (bottom panel) seen in outgrowths from Becn1C/¡
MEC transplantation. (G) Similar F4/80 staining detected in outgrowths from Becn1C/C and Becn1C/¡ MEC transplanta-
tion. (H) Increased 8-O-dG is seen in outgrowths from Becn1C/¡ MEC transplantation. *P < 0.05, **P < 0.01, and ***P <
0.001 by a 2-tailed Student t test. Scale bar: (A, C, F, G, and H) 30 mm; (E) 50 mm.
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outgrowths exhibited increased oxidative stress, as evaluated by 8-
oxo-7,8-dihydroguanine (8-O-dG) staining (Fig. 5H).
Becn1C/¡ mice develop spontaneous mammary tumors
following parity
In earlier studies which reported mammary hyperplasias, but
no mammary tumors, in Becn1C/¡ mice independent of age and
parity,4,15 the mouse genetic background was C57BL/6, which is
known to suppress mammary tumorigenesis.38 To ensure that
mammary tumor studies in Becn1C/¡ mice were not confounded
by the C57BL/6 status, we changed the genetic background of
Becn1C/¡ mice5 to FVB/N, which is more amenable to mam-
mary tumorigenesis studies.38
Nulliparous and multiparous (post 2 pregnancy/lactation/
involution cycles) Becn1C/C and Becn1C/¡ female mouse cohorts
were generated, cohoused and monitored
for mammary tumor formation. Similar to
C57BL/6 mice,4,15 both nulliparous and
multiparous Becn1C/¡ FVB/N mice devel-
oped lymphomas, lung and liver tumors,
and mammary hyperplasias with age. Fur-
thermore, mammary ducts from older (24-
mo-old) nulliparous Becn1C/¡ FVB/N mice
showed increased cellular density and irreg-
ular epithelial cell layering (Fig. 6A). Simi-
lar, but more pronounced, changes of
increased epithelial density and disorga-
nized ductal architecture were observed in
MGs from multiparous Becn1C/¡ multipa-
rous mice at a younger age (14 to 17 mo)
(Fig. 6B). In contrast to C57BL/6 mice
and nulliparous FVB/N mice, 4 out of 21
mice (19%) of multiparous Becn1C/¡
female mice developed mammary tumors
between the ages of 14 and 24 mo
(Fig. 6C). Tumor #1 displayed squamous
and focal glandular differentiation, with
keratinizing differentiated squamous
and nonkeratinized poorly differentiated
regions. Tumor #2 displayed well-differen-
tiated keratinizing squamous differentiation
with foci of basaloid squamous and glandu-
lar components; both tumors #1 and 2
showed pervasive KRT6- and KRT14-posi-
tivity, but no PGR staining. Tumor #3 had
characteristics of glandular differentiation
with small foci of well-differentiated kerati-
nizing squamous component, and was posi-
tive for KRT6 and KRT14, but not PGR.
Tumors #1–3 were characterized as invasive
adenosquamous carcinomas, a type of meta-
plastic carcinoma seen in the mammary
gland. Tumor #4 displayed a marked cribri-
form pattern and luminal eosinophilic cyl-
inders resembling the invasive mammary
tumor known as an adenoid cystic carci-
noma, and was KRT6-negative, but PGR-
positive. Despite diversity in histology likely
due to tumor heterogeneity,39 most tumors
were squamous, KRT6-positive, and basal-
like (KRT14-positive) and all showed nega-
tive correlation between KRT6 and PGR
expression.
Figure 6. Spontaneously arising mammary tumors are detected in multiparous Becn1C/¡ FVB/N
mice. (A and B) Hematoxylin and eosin staining (H&E) of MG sections from Becn1C/C (left) and
Becn1C/¡ (right) FVB/N mice: (A) Representative images from MGs of nulliparous 21- to 22-mo-old
mice reveals increased epithelial cell density and inﬂammatory cell inﬁltration (brown, identiﬁed
with arrow) in Becn1C/¡ mice. (B) Representative H&E images of MGs from parous 14- to 17-mo-
old mice reveals increased epithelial cell density and disorganized cell layering in MGs from
Becn1C/¡ mice. (C) Representative images from 4 spontaneously arising mammary tumors in par-
ous Becn1C/¡ FVB/N mice (Tumors #1 to 4). Left panels are representative H&Es; middle panels,
KRT6 (green) and nuclear PGR (red) staining; and right panels, KRT8 (green) and KRT14 (red) stain-
ing. (*) and (*) denote keratin pearls and basement membrane/eosinophilic hyaline materials,
respectively. Tumor type denotations are identiﬁed by: (i) for glandular components, (ii) for poorly
to moderately differentiated squamous cell carcinoma, (iii) for well-differentiated squamous cell
carcinoma, and (iv) for basaloid squamous cell carcinoma. Scale bar: (A and B) 30 mm and KRT8
and KRT14 (C); (C) 200 mm for H&Es; (C) 50 mm for KRT6 and PGR.
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Monoallelic Becn1 loss accelerates
WNT1-driven mammary tumorigenesis
Given our findings that monoallelic
Becn1 loss promotes KRT6-positive imma-
ture mammary cell accumulation (Fig. 1),
we investigated whether Becn1 heterozygos-
ity has an impact on mammary tumorigen-
esis in the context of oncogenic WNT1
activation, where KRT6-positive bipotent
MaPCs are considered tumor-initiating
cells.18,20
As shown (Fig. 7A; Fig. S5A), Becn1C/¡;
MMTV-Wnt1 mice displayed significantly
shorter mammary tumor-free survival (4 vs.
7.2 mo; P 0.004) and overall survival (4.7 vs.
7.5 mo; P < 0.001) compared with Becn1C/
C;MMTV-Wnt1 mice. Consistent with
defective autophagy status, mammary tumors
from Becn1C/¡;MMTV-Wnt1 mice showed
reduced LC3B levels and SQSTM1 aggre-
gates (Fig. S5B). Tumors arising in Becn1C/
C;MMTV-Wnt1 mice displayed known
characteristics of MMTV-Wnt1 mammary
tumors,40 as they were KRT6-positive
adenosquamous carcinomas with high KRT8
and low KRT14 levels, and variable ESR
(estrogen receptor) and PGR expression
(Fig. 7B). Mammary tumors from Becn1C/¡;
MMTV-Wnt1mice were also mostly adenos-
quamous carcinomas, but exhibited higher
KRT6 levels, were more basal-like, as KRT14
expression was very prominent, and did not
express ER or PGR (Fig. 7B). Furthermore,
while proliferation was similar, apoptosis was
suppressed in tumors from Becn1C/¡;
MMTV-Wnt1mice (Fig. S5C and S5D).
Gene expression profiling also showed
that mammary tumors from Becn1C/¡;
MMTV-Wnt1 mice showed higher expres-
sion of KRT6 and other basal keratins,
including KRT5, KRT14, and KRT17;
they also displayed CTNNB1/b-catenin
(catenin [cadherin-associated protein], b 1,
88 kDa) upregulation (Fig. 7C), indicating
that monoallelic Becn1 loss rendered
WNT1-induced mammary tumors basal-
like and further enhanced CTNNB1
signaling already present due to WNT1
activation. An earlier publication reported
that TP53 expression is regulated by
BECN1 and, as such, may contribute to
BECN1-associated tumor suppression.41 In
our studies, mammary tumors from
Becn1C/C;MMTV-Wnt1 and Becn1C/¡;
MMTV-Wnt1 mice did not exhibit differ-
ences in expression of TP53 transcriptional
Figure 7. Monoallelic Becn1 loss accelerates WNT1-driven tumorigenesis and gives rise to mam-
mary tumors with TNFRSF11A-NFKB1 pathway activation and basal-like characteristics. Basal-like
characteristics and TNFRSF11A-NFKB1 signaling activation are detected in spontaneous mammary
tumors that arise faster in Becn1C/¡;MMTV-Wnt1 (right) compared with Becn1C/C;MMTV-Wnt1
mice (left). (A) Kaplan-Meier curves for mammary tumor-free survival in Becn1C/C;MMTV-Wnt1 (n
D 25) and Becn1C/¡;MMTV-Wnt1 (n D 20) mice demonstrates decreased mammary tumor-free
survival in Becn1C/¡;MMTV-Wnt1 mice. (B–E) Examination of mammary tumors and premalignant
MGs from Becn1C/C;MMTV-Wnt1 (left) and Becn1C/¡;MMTV-Wnt1 (right) mice. (B) Representative
images of H&E staining (top panel), KRT6 (green) and nuclear PGR (red) cell staining (second
panel), KRT8 (green) and KRT14 (red) cell staining (third panel), and nuclear ESR1 staining (bottom
panel) on tumor sections. (C) Heat map representation of microarray analysis conﬁrms basal-like
tumor characteristics along with higher CTNNB1 expression in tumors from Becn1C/¡;MMTV-Wnt1
mice. Statistical signiﬁcance of upregulation of a given signature on a group of samples was deter-
mined using a Fischer exact test for enrichment of samples with signiﬁcant (P < 0.05) signature
expression in the group relative to samples outside the group. (D) Representative images of
TNFSF11 (top panel) and RELA (bottom panel) expression in mammary tumors, and (E) TNFSF11
(top panel), TNFRSF11A (center panel), and RELA (bottom panel) expression in premalignant MGs
from 6- to 10-wk-old cohoused Becn1C/C;MMTV-Wnt1 and Becn1C/¡;MMTV-Wnt1 littermates. P <
0.01 determined by a Mantel-Cox test for Kaplan-Meier curves. Scale bar: (B) 200 mm for H&Es; (B,
D, and E) 30 mm for all other panels.
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target genes (data not shown), thus suggesting that in the context
of WNT1-driven mammary tumorigenesis, differential TP53
activation is not a likely contributor to mammary tumor accelera-
tion in association with monoallelic Becn1 loss.
Consistent with our finding that monoallelic Becn1 loss results
in increased mammary stem and progenitor cell activity in associ-
ation with TNFRSF11A-NFKB pathway activation (Figs. 1, 3,
and 4), tumors from Becn1C/¡; MMTV-Wnt1 mice exhibited
increased TNFSF11 expression and nuclear RELA staining
(Fig. 7D). Premalignant MGs from Becn1C/¡;MMTV-Wnt1
mice displayed even higher TNFSF11, TNFRSF11A, and
nuclear RELA levels (Fig. 7E), indicating that early activation of
TNFRSF11A-NFKB signaling may contribute to promotion of
WNT1-driven mammary tumorigenesis by monoallelic Becn1
deletion. However, additional studies must be conducted to
further investigate whether aberrant TNFRSF11A pathway
activation is responsible for the accelerated mammary tumor
development in Becn1C/¡;MMTV-Wnt1 mice.
Human breast cancers with low BECN1 mRNA expression
and an activated WNT pathway gene signature have poor
prognosis
To examine the clinical relevance of our mouse tumor studies,
we identified human breast cancers exhibiting a gene signature
consistent with WNT pathway activation and stratified them for
high vs. low (above or below the mean across samples, respec-
tively) expression of BECN1 mRNA. In 2 independent breast
cancer cohorts,42,43 tumors with low BECN1 expression and an
activated WNT pathway gene signature had significantly worse
prognosis than tumors with high BECN1 mRNA and WNT
pathway activation (Fig. 8A and B) and also correlated with the
triple negative breast cancer (TNBC) subtype (Fig. 8C and D).
In a cohort excluding ERBB2-positive cancers,42 tumors with
low BECN1 expression and an activated WNT pathway gene sig-
nature were almost exclusively TNBCs and showed TNFRSF11A
pathway activation (Fig. 8D), similar to mammary tumors from
Becn1C/¡;MMTV-Wnt1 mice (Fig. 7C).
In the Sabatier data set,43 within low BECN1-expressing
tumors, an activated WNT pathway gene signature conferred
worse disease-free survival (DFS), whereas in high BECN1-
expressing tumors, it was associated with improved DFS (Fig.
S6A). In tumors not displaying WNT pathway activation,
BECN1 expression did not affect DFS (Fig. S6A). In the Hatzis,
ERBB2-negative breast tumor database, in low BECN1-express-
ing and mostly triple-negative tumors, WNT pathway activation
did not have an impact on DFS, whereas in high BECN1-
expressing tumors, it was again associated with improved DFS
(Fig. S6B). In tumors not displaying upregulation of a WNT
pathway gene signature, low BECN1 expression conferred worse
DFS (Fig. 6B). Examination of additional breast cancer data-
bases and prospective evaluation of clinically annotated breast
tumor biopsies will be necessary to further define how the com-
bination of low BECN1 expression and WNT pathway activa-
tion affects prognosis within the different breast cancer
subtypes.
Discussion
Role of Becn1 in the homeostasis of the mammary cell
hierarchy
Our studies identify monoallelic Becn1 loss as a potential con-
tributor to immature MEC expansion and, thus, deregulation of
the mammary cell hierarchy. Our findings come at a time of great
interest in the role of autophagy in stem and progenitor cell biol-
ogy. Recent studies show that autophagy supports stem cell sur-
vival in the hematopoietic44 and nervous45 systems, and in the
context of an ERa-positive and an ERBB2-positive breast cancer
cell lines.10 Here we report that partial Becn1 deficiency leads to
increased mammary stem and progenitor cell activities, and we
hypothesize that this contributes to increased mammary tumori-
genesis in association with monoallelic Becn1 loss under condi-
tions of further mammary stem and progenitor pool expansion
due to either parity or activation of particular oncogenes, such as
WNT1. Our work identifies 2 specific contexts in which Becn1
heterozygosity promotes mammary tumorigenesis, and provides
insight into the seemingly paradoxical roles of BECN1, and
autophagy in general, as both tumor-suppressive and tumor-pro-
moting functions. Furthermore, our studies suggest that low
BECN1 expression has an impact on tumor histology in the case
of WNT1-driven tumorigenesis, giving rise to tumors with more
basal and TNBC characteristics.
An important question that arises from this work and the
focus of future studies is whether the Becn1 heterozygosity-associ-
ated mammary phenotypes described in our study are secondary
to nonautophagy-related roles of BECN1 in mammary develop-
ment and tumorigenesis. Although the impact of conditional
Atg7 deficiency on mammary tumor formation following parity
or WNT1 activation has not yet been explored, it is intriguing
that biallelic Atg7 deletion delays mammary fat pad filling during
puberty and does not result in the hyper side-branching pheno-
type observed in Becn1C/¡ mice, pointing to a BECN1-specific,
and unrelated to autophagy, role in ductal morphogenesis. Alter-
natively, an autophagy dosage effect on mammary hierarchy may
contribute to the observed phenotypes. In that respect, a more
severe autophagy defect, such as that conferred by biallelic Atg7
loss, may drastically compromise MaSC and progenitor cell sur-
vival, and possibly suppress tumorigenesis, whereas partially defi-
cient autophagy due to Becn1 heterozygosity may result in
“injured,” but still surviving, mammary stem and progenitor cells
with increased proliferation, which may promote tumor develop-
ment under conditions that further deregulate the homeostasis of
mammary cell hierarchy; an autophagy dosage effect on mam-
mary differentiation and possibly tumorigenesis would be consis-
tent with the results of recent studies on the role of autophagy
inhibition in lung cancer.11
Monoallelic Becn1 loss and TNFRSF11A-NFKB signaling
activation in mammary tissues
Our studies demonstrate that MGs from pubertal and adult
Becn1C/¡ mice exhibit excessive ductal side-branching in associa-
tion with abnormal TNFSF11 expression and TNFRSF11A-
NFKB axis activation. TNFSF11 is a member of the tumor
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necrosis factor (TNF) ligand superfamily,
primarily known for its role in bone remod-
eling and metastasis33 and also implicated in
MaPC expansion and progestin-induced
tumorigenesis.34,46 High TNFRSF11A and
TNFSF11 levels were also reported in breast
cancers lacking ESR1 and PGR expression
and in high-grade and highly proliferative
breast tumors;47 consistent with these
results, we also found evidence of
TNFRSF11A pathway activation in aggres-
sive basal-like tumors exhibiting low
BECN1 expression and an activated WNT
pathway gene signature. Furthermore,
TNFRSF11A overexpression in breast can-
cer cell lines has been reported to disrupt
mammary cell fate, induce epithelial-to-
mesenchymal transition (EMT) and pro-
mote mammary tumorigenesis and metasta-
sis.47 In our studies, tumors originating in
both Becn1C/C;MMTV-Wnt1 and Becn1C/
¡;MMTV-Wnt1 mice retained epithelial
keratin expression, and neither expressed
mesenchymal markers, such as VIM/vimen-
tin (data not shown) nor gave rise to visible
metastases at the time of necropsy.
However, since metastatic lesions are not
usually noted in MMTV-Wnt1 mice sacri-
ficed when their primary mammary tumors
reach experimental endpoints,40 specifically
designed metastasis studies, involving mam-
mary tumor resection survival surgery and/
or intracardial injection of tumor-derived
mammary tumor cell lines, will be necessary
to determine the role of BECN1 in metasta-
sis and EMT in the context of WNT path-
way activation.
Our findings, together with the striking
similarities in mammary development and
tumor phenotypes between Becn1C/¡ and
MMTV-Tnfrsf11a (or MMTV-Tnfsf11)
mice, suggest that the TNFRSF11A path-
way may mediate the impact of monoallelic
Becn1 loss on mammary cell hierarchy, mor-
phogenesis and tumorigenesis. However,
whether ectopic TNFRSF11A pathway acti-
vation is responsible for, or contributes to,
MaSC and progenitor expansion and
increased tumor susceptibility following
parity or WNT pathway activation upon
monoallelic Becn1 loss requires further mechanistic investigation.
Which cell type produces TNFSF11 in MGs from Becn1C/¡
mice is another topic of interest. TNFSF11 production by
MECs is primarily considered the result of progesterone stimula-
tion,28,32 whereas in macrophages, adipocytes, and breast cancer
cells, proinflammatory cytokines can also upregulate
TNFSF11.36,48,49 Our transplantation studies argue in support
of TNFSF11 production by MECs in response to proinflamma-
tory cytokine release by MECs themselves: (1) mammary out-
growths were exposed to same systemic progesterone levels, as
CD24C CD29hi Becn1C/C and Becn1C/¡ MECs were trans-
planted in contralateral fat pads of recipient mice. Increased
Figure 8. Human breast cancers with low BECN1 expression and an activated WNT pathway gene
signature have poor prognosis. (A–D) Kaplan-Meier curves and GSEA for breast tumors displaying
an activated WNT pathway gene signature and stratiﬁed for BECN1 expression (see Methods).
(A) Disease-free survival for patients with breast cancers annotated in the Sabatier cohort (P 7.2
£ 10¡5). (B) Disease-free survival for patients with ERBB2-negative breast cancers annotated in
the Hatzis cohort (P 2.7 £ 10¡3). Gene expression analysis comparison in (C) the Sabatier cohort
and (D) the Hatzis cohort reveals that breast cancers with low BECN1 and an activated WNT path-
way gene signature are primarily triple-negative, have basal-like characteristics, and display
TNFRSF11A pathway activation and higher CTNNB1. P values were calculated by the Fischer exact
test (see Materials and Methods). (E) Model for the cooperation between monoallelic BECN1 loss
and WNT pathway activation in mammary tumorigenesis. *P < 0.05, **P < 0.01, ***P < 0.001.
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progesterone signaling in association with monoallelic Becn1 loss
must therefore result from a locally-induced expansion of PGR-
expressing cells; (2) 2 proinflammatory cytokines known to
induce TNFSF11 production, namely IL1B and TNF, were
detected in CD24C CD29hi Becn1C/¡ MEC-generated out-
growths; (3) CD24C CD29hi Becn1C/C and Becn1C/¡ MEC
transplantations were performed in wild-type recipient mice,
thus all stromal cells were wild type. The fact that, similar to
MGs from Becn1C/¡ mice, outgrowths from CD24C CD29hi
Becn1C/¡ MEC transplantation also exhibited increased ductal
side-branching and TNFSF11 production indicate that MECs
are sufficient to induce these mammary phenotypes. Further-
more, macrophage infiltration was similar in CD24C CD29hi
Becn1C/C and Becn1C/¡ MEC-generated outgrowths; (4)
increased oxidative stress, a inducer of proinflammatory cytokine
production,37 was documented in CD24C CD29hi Becn1C/¡
MEC-generated outgrowths; (5) autophagy-deficient status,
commonly associated with inflammation and cytokine
release,14,37 was maintained in CD24C CD29hi Becn1C/¡ MEC-
generated outgrowths. This study provides evidence for an essen-
tial role of BECN1 in restricting mammary stem and progenitor
cell expansion and limiting ectopic TNFRSF11A pathway activa-
tion, 2 pathways known to be deregulated in particular contexts
of mammary tumorigenesis.18,30,34
Shedding light in the complex role of Becn1 in mammary
tumorigenesis
BECN1, and autophagy in general, have complex roles in
tumorigenesis: allelic BECN1 deletions have been reported in
human cancers,2 and Becn1C/¡4,5 and other Atg-deficient50,51
mice are tumor-prone, in support of a tumor suppressor role for
autophagy in cancer. However, autophagy also preserves tumor
cell survival under stress and likely contributes to tumor progres-
sion11 and treatment resistance.52 While apoptosis-deficient
Becn1C/¡ iMMECs, compared with their wild-type counterparts,
result in earlier mammary tumor development in nude mice,6
monoallelic Becn1 deletion does not alter ERBB2- or PyMT-
driven,8 while it delays Palb2 loss-associated,13 mammary
tumorigenesis.
Our studies define specific contexts, either following parity or
oncogenic WNT1 activation, in which monoallelic Becn1 dele-
tion promotes mammary tumorigenesis. Spontaneous tumors
arising in Becn1C/¡ mice after parity display mostly squamous
cell characteristics, which is similar to the squamous differentia-
tion seen by Wei and colleagues in lung cancers with low BECN1
expression.9 These 2 studies indicate that low BECN1 expression
may drive particular lung and breast cancer subsets toward squa-
mous, rather than adenocarcinoma, histologies, thus also raising
the possibility of concurrent EGFR activation.
In the case of WNT pathway activation, we propose that
WNT1-driven mammary stem and progenitor cell expansion
cooperates with Becn1 heterozygosity-induced deregulation of
the mammary hierarchy to create more transformation-suscepti-
ble immature mammary cells (Fig. 8E). Since monoallelic Becn1
loss results in hormone receptor-negative, basal-like mammary
tumors, it is possible that corresponding tumor-initiating cells
(TICs) reside within the expanded mammary stem and progeni-
tor cell populations,23 a hypothesis that is worthy of further
investigation. If this is the case, other oncogenes deregulating the
mammary hierarchy and resulting in expansion of progenitor cell
populations may also cooperate with monoallelic Becn1 loss to
promote mammary tumorigenesis.
Low BECN1 expression and an activated WNT pathway
gene signature define a breast cancer subset with poor prognosis
Despite the early discovery that WNT signaling is highly
oncogenic in the mammary gland,18,20 conclusive evidence that
it is a tumor-driver in breast cancer lagged behind.53 In contrast
to colorectal tumors, which commonly harbor mutations in
canonical WNT pathway genes,54 breast cancers lack such
genetic alterations.55 However, even in the absence of mutations,
canonical WNT pathway activation has been documented in
TNBCs by increased CTNNB1 expression and nuclear localiza-
tion in association with overexpression of the WNT receptor
LRP6 (low-density lipoprotein receptor-related protein 6).56
Also, single nucleotide polymorphisms (SNPs) in WNT pathway
genes were associated with ESR1-negative breast cancer risk.57
Given (1) that monoallelic Becn1 loss accelerates WNT1-
driven mammary tumorigenesis and results in basal-like mam-
mary tumors, and (2) the shift in focus from mutational analysis
to collective upregulation of WNT signaling in tumors,58 we
interrogated human breast cancer databases for BECN1 expres-
sion and WNT pathway activation, using DNA probes for
BECN1 and a KEGG pathway-annotated gene signature for
WNT pathway (hsa04310; http://www.genome.jp/dbget-bin/
www_bget?hsa04310). We found that breast tumors with low
BECN1 expression and WNT pathway activation comprise 24–
36% of TNBCs and confer poor patient prognosis. Similarities
between mammary tumors from Becn1C/¡;MMTV-Wnt1 mice
and human breast cancers with low BECN1 levels and WNT
pathway activation, i.e. basal-like characteristics, TNFRSF11A
pathway activation, and tumor aggressiveness, indicate that our
mouse tumor model recapitulates molecular features and out-
comes of a sizeable TNBC subgroup. Thus, our mouse model is
a unique and clinically relevant preclinical model for a particular
subset of breast cancers, and provides a valuable tool to develop
useful molecular markers and evaluate targeted approaches for
the treatment of these aggressive malignancies. Furthermore, our
analysis of human breast cancer gene expression profiling indi-
cates that, rather than genomic BECN1 alterations which may
not have an impact on breast tumorigenesis,16 BECN1 mRNA
expression, which can also be transcriptionally and/or epigeneti-
cally regulated, may itself determine breast cancer susceptibility
under particular circumstances, such as parity or WNT pathway
activation, and thus act as a context-dependent tumor suppressor.
Identifying an aggressive TNBC subtype with low BECN1
expression and activation of both WNT and TNFRSF11A path-
ways has the potential to greatly advance targeted breast cancer
treatment, given that WNT signaling inhibitors are clinically
investigated and a TNFRSF11A pathway inhibitor, denosumab,
is already FDA-approved for prevention and treatment of osteo-
porosis and skeletal-related events in patients with bone-
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metastatic solid malignancies.59 The mechanistic relationship
between low BECN1 expression, an activated WNT pathway
gene signature and aberrant TNFRSF11A signaling in breast
tumors needs to be further investigated to justify pharmacologic
targeting of the TNFRSF11A and/or WNT pathways for treat-
ment of such malignancies. Given our finding that monoallelic
Becn1 loss results in mammary stem and progenitor cell expan-
sion, which may in turn contribute to acceleration of WNT-
driven tumorigenesis, it is conceivable that mammary stem and
progenitor tumor cells may arise as promising therapeutic targets
in the treatment of aggressive breast cancers exhibiting low
BECN1 expression and an activated WNT pathway gene
signature.
Altogether our studies identify BECN1 as a mammary tumor
suppressor in 2 particular contexts, namely spontaneous mam-
mary tumor formation following parity and WNT1-driven
oncogenesis.
Materials and Methods
Mice
For native mammary gland experiments, mice were housed at
the Child Health Institute of New Jersey, in pathogen-free facili-
ties, and cared for as per IACUC-approved protocols. For trans-
plantation experiments, recipient mice were housed at Princeton
University and procedures were in compliance with IACUC-
approved protocols. Becn1C/¡ mice5 were obtained from Dr S
Jin. MMTV-Wnt1 mice were obtained from Dr Y Li. Atg7F/F
mice26 were obtained from Dr Komatsu. Gfp-Lc3 mice were
obtained from Dr Mizushima. Krt14-Cre mice60 were obtained
from Jackson Laboratories.
For CD61 analysis and tumor studies, C57BL/6 Becn1C/¡
mice were backcrossed to FVB/N for 10 generations. In vitro
MaSC and progenitor cell assays were performed in both
C57BL/6 and FVB/N backgrounds. For all other studies involv-
ing the Becn1C/¡ genotype, C57BL/6 mice were used. For mam-
mary fat pad filling and ductal side-branching cohoused
littermates (for pubertal time points) and cohoused (for at least 3
mo after last pregnancy) multiparous mice were compared. At
least 3 animals were compared for each time point. For all immu-
nostaining, littermates or outgrowths from the same recipient
mouse were compared. For tumor studies, multiparous mice
were cohoused after 2 rounds of pregnancy, nursing, and wean-
ing of their litters. Mice from the multiparous and nulliparous
cohorts were palpated weekly for mammary tumor detection. For
ovariectomization and stimulation studies procedures were per-
formed as previously described.32
Mammosphere and colony-forming assays
Primary mammosphere assays were performed as previously
described.23,25 MaSC viability assays under ultra low attachment
were performed as previously described, and mammospheres
were counted. 20,000 CD24C CD29hi MECs per well were
plated on ultra-low attachment plates (Costar, 3471) for 10 to
15 d in Dulbecco’s modified Eagle’s medium (DMEM)/F12,
EGF (epidermal growth factor; Sigma, E4127), FGF2 [fibroblast
growth factor 2 (basic); Invitrogen, PHG0026], B27 (Gibco,
17504-044), and heparin (Sigma, H6279). Results are presented
as means§ standard deviation (SD) from 3 independent experi-
ments. Primary mammospheres (2 or more cells) were counted.
For limiting dilution mammosphere assays, 25 to 500 CD24C
CD29hi MECs per well were plated in duplicate.
The 3D colony-forming assays were performed as previously
described.23,25 20,000 CD24C CD29hi MECs per well were
plated in reduced growth factor Matrigel (BD, 354230) and sup-
plemented with mammary epithelial growth medium (MEGM)
(Lonza, CC3051A), 5% FBS, EGF, and FGF2. Colonies were
counted after 9 to 14 d. Results are presented as means§ SDs
from 3 independent experiments.
The 2D colony-forming assays were performed as previously
described.23,25 1,000 CD24C CD29lo cells per well were plated
on reduced growth factor Matrigel, supplemented with MEGM,
10% FBS, EGF, FGF2. Colonies were counted after 7 to 9 d.
Results are presented as means § SDs from 3 independent
experiments.
Transplantation assays
MECs were isolated as previously described.22 FACS was used
to collect CD24C CD29hi MECs, i.e., the MaSC-containing
population, and transplantations were performed as previously
described into cleared fat pads of 3- to 4-wk-old recipient wild-
type C57BL/6 female mice,22 in accordance with IACUC-
approved protocols. Primary MEC donors were littermates.
CD24C CD29hi MECs were injected in a 200 mL volume
(100 mL reduced growth factor Matrigel C 100 mL 1£ phos-
phate-buffered saline (PBS; Gibco, 14190) at cell numbers speci-
fied. Mammary outgrowths were allowed to grow for 6 wk
following transplantation and were then dissected, mounted on
microscope slides, and processed for histological analysis. Three
independent transplantation experiments were performed.
Mammary gland whole mounting
Native mammary glands from pubertal mice and mammary
outgrowths generated by CD24C CD29hi MEC transplantation
were mounted onto microscope slides and fixed in 10% formalin
overnight. Mammary glands from aged mice were mounted on
microscope slides and fixed in Carnoy fixative for de-fatting.
Mounts were then subjected to graded ethanol to water washes,
and stained with carmine solution (Sigma, C1022 prepared as
directed, with Aluminum Potassium Sulfate, Sigma, A7167)
overnight with shaking. Stained slides were then subjected to
graded water to ethanol washes, destained and stored in Histo-
Clear II (National Diagnostics, HS-202). Imaging was done on
Olympus SZ61 dissecting microscope (Rutgers Cancer Institute
of New Jersey) using the ProRes Capture Pro2.5 software.
Stable cell lines and culture conditions
Cells were maintained in F12 (Gibco, 11765), 10% FBS, 1%
penicillin/streptomycin, 5 ng/mL EGF, 1 mg/mL hydrocorti-
sone (Sigma, H0888), 5 mg/mL insulin (Sigma, I9278). Cells
were plated on glass coverslips, and allowed to attach overnight.
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For immunofluorescence (IF), cells were fixed with 1:1 methanol:
acetone at ¡20 C for 10 min and rinsed with 1£ PBS. Slides
were incubated with 50 mL KRT6 primary antibody 1:200 in
3% bovine serum albumin (BSA; Benchmark, 100-106), 0.01%
Tween 20 (BIO-RAD, 170-6531), 1£ PBS at 37 C for 90 min
with shaking. After washing with 0.01% Tween 20, 1£ PBS,
slides were incubated with 50 mL FITC-conjugated anti-rabbit
antibody (Jackson ImmunoResearch, 711-095-152) 1:100 in 3%
BSA, 0.01% Tween 20, 1£ PBS at 37 C for 30 min with shak-
ing. Cells were stained with DAPI (Invitrogen, P36931) and
mounted with ProLong Gold Antifade Mounting Media (Life
Technologies, P363930). Slides were imaged using the Olympus
1£51 scope and Metamorph Image program.
Primary MEC isolation and FACS for MEC subpopulations
Primary MECs were isolated as previously described.22,23,25
MECs were stained as previously described22,23 and sorted using
FACSVantage SE with DiVa (BD) at Princeton University.
LIN¡ refers to cluster differentiation 31 (CD31)¡, cluster differ-
entiation 45 (CD45)¡, and erythroid-specific LY76 (lymphocyte
antigen 76)¡ negative cells, i.e. MECs. CD24C CD29hi MECs
refer to a MaSC-containing population, CD24C CD29lo to a
mammary progenitor cell-containing, and CD24¡ to differenti-
ated MECs, as previously described.22,23 FACS profiles were ana-
lyzed using FlowJo software (TreeStar, Inc.). Five independent
experiments were performed.
Primary and stable cell lines
Immortalized mouse mammary epithelial cells were generated
as previously described.6 MaSC and MaPC colony- and mam-
mosphere-forming assays were performed as previously
described.23,25 MaSC transplantations were performed as previ-
ously described.22
Histology of tissues and tumors
Mammary tissues were processed and imaged as previously
described.15 Following Carmine staining, mammary glands and
outgrowths from CD24C CD29hi MEC transplantation were
transferred to 70% ethanol overnight, and processed as above.
Hematoxylin and eosin (H&E) staining and imaging were per-
formed by the Histopathological and Imaging Core Facility at
Rutgers Cancer Institute of New Jersey.
Antibodies
For flow cytommetry, CD31 (BD558737), CD45
(B553078), LY76/TER119 (BD553672), and CD24-PE
(BD553262) antibodies were from BD Biosciences, CD61-APC
(MCD6105) from Invitrogen, and CD29-FITC (MCA2298FB)
from Serotech were used. For immunohistology, KRT6 (PRB-
169P) from Covance, KRT17 (ab53707), TNF/TNFa
(ab8871), F4/80 (ab6640), and 8-O-dG (ab48508) from Abcam,
KRT14 (gift from Dr Segre), PGR (gift from Dr Clarke), CASP3
(9661) from Cell Signaling Technology, MKI67 (NCL-L-Ki67-
MM1) from Leica, ESR1/ERa (sc-542) and RELA/p65 (sc-
8008) from Santa Cruz Biotechnology, TNFRSF11A/TNR11
(AF692) and TNFSF11/TNF11 (AF462) from R&D Systems,
SQSTM1 (BML-PW9860) from Enzo, LC3 (NB100-2331) and
IL1B/IL-1b (NBP1-19775) from Novus Biologics, and KRT8
(TROMA-1) and BrdU (G3G4) from the Developmental Stud-
ies Hybridoma Bank were used.
Immunostaining
For immunohistochemistry (IHC), slides were deparrafinized
with xylenes, rehydrated with ethanol to water washes, and boiled
at 97 C for 16 min in 1£ Antigen Unmasking Solution (Vec-
tor, H-3300). For PGR staining, retrieval was done by autoclav-
ing at 121 C, 16 to 17psi, for 30 min in Vector 1£ unmasking
solution. For ESR1 staining, retrieval was done by microwaving
slides in 1£ Vector Unmasking Solution for 20 min. Slides were
washed in water, followed by endogenous peroxidase blocking
with 3% H2O2. Washes in 0.05% Tween 20 in 1£ PBS or
0.05% Triton X-100 (Sigma, X100) (for PGR) were performed
before blocking for 1 h at room temperature in 5% goat serum
albumin for rabbit antibody, 5% BSA for goat antibody, or
MOM Blocking Reagent (Vector, MKB-2213) for mouse or rat
antibodies. For ESR1 staining, retrieval was done by microwav-
ing slides in 1£ Vector Unmasking Solution for 20 min. For
rabbit and goat antibodies, primary antibodies were added in
blocking reagent overnight at 4 C. Biotin-conjugated anti-rabbit
1:1000 (Novus, NB 730-B) in 5% goat serum albumin (Jackson
ImmunoResearch, 005-000-001)or anti-goat 1:500 (Jackson
ImmunoResearch, 711-065-152) in 5% BSA were added to slides
for 1 h at room temperature. For rat and mouse antibodies, pri-
mary antibodies were added in MOM diluent (prepared as per
MKB-2202) for 30 min at room temperature as directed. For rat
antibody, biotinylated anti-rat (Dako, E0468) 1:500 was added for
1 h at room temperature. For mouse antibody, biotinylated anti-
mouse antibody (MKB-2225) 1:250 in MOM diluent was added
at room temperature for 10 min (15 min for PGR). For all anti-
bodies, sections were washed with 0.05% Tween 20 in 1£ PBS,
then incubated in Vector Elite ABC reagent (PK-7100) for 30 min
at room temperature. For ESR1, an additional Streptavidin-HRP
(Vector, SA-5704) incubation step was performed for 30 min as
room temperature. All sections were incubated in DAB C chromo-
gen substrate (Dako, K3468) for 10 min (15 min for PGR and
ESR1), and counterstained with Harris Modified Hematoxylin 1:5
(Fischer Scientific, SH26-500D). Slides were mounted with Per-
mount medium (Fisher Scientific, SP15-100). Imaging was done
with an Olympus 1£51 microscope, Jenoptik Laser Optik camera
system (Rutgers Cancer Institute of New Jersey), and ProgRes
C10Plus software.
For immunofluorescence (IF), slides were deparrafinized with
xylene, rehydrated with ethanol to 1£ PBS washes, and boiled at
97 C for 16 min in 1 M Urea (Bio-Rad, 161-0730) or 1£ Vec-
tor Unmasking Solution (TNFSF11 only). For PGR staining,
retrieval was done by autoclaving slides at 121 C, 16 to 17 psi,
for 30 min in 1£ Vector Unmasking Solution. Slides were
washed 4 times in water and once in 1£ PBS, followed by block-
ing for 1 h at room temperature in 5% BSA (0.5% Tween-20,
1£ PBS) or MOM Blocking Reagent (1£ PBS for MKI67 and
0.05% Triton X-100, 1£ PBS for PGR). Nonmouse primary
antibodies were added in 5% BSA at room temperature for 2 h,
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except for the TNFSF11 antibody, which was added in 1% BSA,
0.5% Tween 20 overnight at 4 C. PGR antibody was used in
MOM diluent in 0.05% Triton X-100, 1£ PBS for 2 h at room
temperature. Anti-rat, anti-chicken, and anti-rabbit fluorescent anti-
bodies 1:100 (Jackson ImmunoResearch) were used in 5% BSA for
1 h at room temperature. For TNFSF11, biotinylated anti-goat
1:500 (Jackson ImmunoResearch, 711-065-152) was used for 1 h
at room temperature, followed by streptavidin-Texas Red 1:100
(Invitrogen, SA1017) for 30 min. For PGR, biotinylated anti-
mouse 1:250 in MOM diluent in 0.05% Triton X-100, 1£ PBS
was used at room temperature for 15 min, followed by streptavidin-
Texas Red 1:100. For KRT6, CD29 and CD24 costaining, slides
were first stained with KRT6 and CD29 antibodies, anti-rabbit
Alexa-647 1:100 (Invitrogen, A20991) and anti-rat TRITC, then
with the CD24-PE. After all antibody incubations, sections were
washed with 1£ PBS 3 times and mounted with ProLong Gold
antifade with DAPI. Confocal imaging was done using the LSM510
Meta Confocal Laser Scanning Microscope at the Keck Collabora-
tive Neuroscience Center at Rutgers University.
Data quantification and statistical analysis
For all in vitro studies statistics, 2-tailed Student t tests were
performed using http://graphpad.com/quickcalcs/ttest1/. Immu-
nostaining quantification was performed on at least 3 individual
mammary gland specimens, including all TEBs and ducts per
slide. For mammary side-branching quantification, results are
presented as means with standard deviation (§ SD) from 3 mam-
mary gland specimens per genotype from C57BL/6 littermates.
Same results were obtained in FVB/N background. For statistics
on Kaplan Meier curves, Graph Prism software and Mantel-Cox
analysis were utilized.
Mouse mammary tumor gene expression analysis
A minimum of 1 million cells were harvested and lysed directly
from culture plates using 2 mL Trizol (Invitrogen, 15596-026).
Cell lysates were incubated on ice for 5 min, then vortexed for
1 min. Tumors were dissected from mice and snap frozen in liquid
nitrogen. Cell lysates and tumor specimens were given to the Func-
tional Genomics Core Facility at Rutgers CINJ for RNA extraction
and gene expression profiling on Affymetrix Mouse Genome 430
2.0 microarray. Using GeneSpring GX 11.5 (Agilent Technologies,
Inc., Santa Clara, CA, USA), raw gene expression signals were sum-
marized withMAS5. The data was further normalized using baseline
transformation by the median of all samples and log scaling. Fur-
ther, the normalized expression signals were averaged between bio-
logical replicates where applicable. Gene expression data was first
filtered by flags (labeled as “present,” “marginal,” or “absent”).
Probes were only kept if at least one sample was labeled as “present.”
Gene lists were generated by pair-wise comparison. Differentially
expressed genes were designated by looking for a significant fold
change (> 2.0) between the normalized expression values of 2 experi-
ments. Genes were considered significantly stagnant if the fold
change was low (< 1.25).
The generated gene list data were analyzed through the use of
Ingenuity Pathways Analysis (Ingenuity Systems, www.
ingenuity.com). The Functional Analysis identified the biological
functions and/or diseases that were most significant to the data
set. Molecules from the data set that met the fold change cutoff
of 2-fold and were associated with biological functions and/or
diseases in Ingenuity’s Knowledge Base were considered for the
analysis. The right-tailed Fisher exact test was used to calculate a
P value determining the probability that each biological function
and/or disease assigned to that data set is due to chance alone.
Human breast cancer cohorts
The Sabatier43 cohort included 266 breast tumor samples ana-
lyzed with Affymetrix U133 Plus 2.0 Arrays [PMID: 20490655].
The data was downloaded from Gene Expression Omnibus,
series GSE21653. The Hatzis42 cohort included 508 ERBB2-
negative breast tumor samples analyzed with Affymetrix U133A
Arrays [PMID: 21558518]. The data was downloaded from
Gene Expression Omnibus, series GSE25066. Raw CEL files
were processed using the justRMA function in R Bioconductor.
The samples were classified into BECN1 high or BECN1 low
depending on whether BECN1 mRNA expression (probe
208945_s_at) was above or below the average across samples.
WNT pathway gene signature was based on KEGG pathway:
hsa04310 for WNT signaling pathway-Homo sapiens (http://
www.genome.jp/dbget-bin/www_bget? hsa04310). An activated
WNT pathway gene signature was attributed to tumors with sig-
nificant (P < 0.05) upregulation of WNT pathway gene signa-
ture expression relative to the rest of tumors within each breast
cancer cohort; a Fischer exact test was used for this calculation.
Pathway gene signatures
Pathway gene expression signatures (according to KEGG path-
way annotations) were analyzed using Gene Set Enrichment Analy-
sis (GSEA) [PMID: 16199517]. For each sample and signature,
GSEA reports a signature expression score between 0 and 1 and the
statistical significance (P value) for signature overexpression. The sta-
tistical significance of upregulation of a given signature on a group of
samples was determined using a Fischer exact test for enrichment of
samples with significant (P < 0.05) signature expression in the
group relative to samples outside the group.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
We thank Z Yue and S Jin (Mount Sinai School of Medicine
and Rutgers University), Dr Komatsu (Tokyo Metropolitan
Institute of Medical Science), Dr Mizushima (University of
Tokyo), and Y Li (Baylor College of Medicine) for providing
Becn1C/¡, Atg7F/F, GFP-LC3B, and MMTV-Wnt1 mice, respec-
tively. We thank Dr Segre (National Institute of Health) for the
KRT14 antibody and Dr Clarke (Westmead Millennium Insti-
tute) for the PGR antibody. We also thank N Goldsmith-Kane
for assistance with confocal microscopy, the Histopathological,
Imaging, and Functional Genomics Core Facilities at Rutgers
Cancer Institute of New Jersey; also, the Flow Cytometry Facility
at Princeton University. We are indebted to Ed and Sue
2050 Volume 10 Issue 11Autophagy
Goldstein for their unconditional support and encouragement.
This work is dedicated to the memory of Stacy Goldstein.
Funding
We are grateful for financial support from a New Jersey Com-
mission on Cancer Research Predoctoral Fellowship (MC), NIH
grant R00-CA133181 (VK) and a Damon Runyon Clinical
Investigator Award (VK).
Supplemental Material
Supplemental data for this article can be accessed on the
publisher’s website.
References
1. Mizushima N, Levine B, Cuervo AM, Klionsky DJ.
Autophagy fights disease through cellular self-digestion.
Nature 2008; 451:1069–75; http://dx.doi.org/
10.1038/nature06639; PMID:18305538
2. Aita VM, Liang XH, Murty VV, Pincus DL, Yu W,
Cayanis E, Kalachikov S, Gilliam TC, Levine B. Clon-
ing and genomic organization of beclin 1, a candidate
tumor suppressor gene on chromosome 17q21. Geno-
mics 1999; 59:59–65; PMID:10395800; http://dx.doi.
org/10.1006/geno.1999.5851
3. Liang XH, Jackson S, Seaman M, Brown K, Kempkes
B, Hibshoosh H, Levine B. Induction of autophagy
and inhibition of tumorigenesis by beclin 1. Nature
1999; 402:672–6; http://dx.doi.org/10.1038/45257;
PMID:10604474
4. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel
A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y,
et al. Promotion of tumorigenesis by heterozygous dis-
ruption of the beclin 1 autophagy gene. J Clin Invest
2003; 112:1809–20; http://dx.doi.org/10.1172/
JCI20039; PMID:14638851
5. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an
autophagy gene essential for early embryonic develop-
ment, is a haploinsufficient tumor suppressor. Proc
Natl Acad Sci U S A 2003; 100:15077–82; http://dx.
doi.org/10.1073/pnas.2436255100; PMID:14657337
6. Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G,
Mathew R, Jin S, White E. Autophagy mitigates
metabolic stress and genome damage in mammary
tumorigenesis. Genes Dev 2007; 21:1621–35;
PMID:17606641; http://dx.doi.org/10.1101/gad.
1565707
7. Rosenfeldt MT, O’Prey J, Morton JP, Nixon C,
MacKay G, Mrowinska A, Au A, Rai TS, Zheng L,
Ridgway R, et al. p53 status determines the role of
autophagy in pancreatic tumour development. Nature
2013; 504:296–300; http://dx.doi.org/10.1038/
nature12865; PMID:24305049
8. Lozy F, Cai-McRae X, Teplova I, Price S, Reddy A,
Bhanot G, Ganesan S, Vazquez A, Karantza V. ERBB2
overexpression suppresses stress-induced autophagy and
renders ERBB2-induced mammary tumorigenesis inde-
pendent of monoallelic Becn1 loss. Autophagy 2014;
10:662–76; PMID:24492513; http://dx.doi.org/
10.4161/auto.27867
9. Wei Y, Zou Z, Becker N, AndersonM, Sumpter R, Xiao
G, Kinch L, Koduru P, Christudass CS, Veltri RW, et al.
EGFR-mediated Beclin 1 phosphorylation in autophagy
suppression, tumor progression, and tumor chemoresist-
ance. Cell 2013; 154:1269–84; http://dx.doi.org/
10.1016/j.cell.2013.08.015; PMID:24034250
10. Gong C, Bauvy C, Tonelli G, Yue W, Delomenie C,
Nicolas V, Zhu Y, Domergue V, Marin-Esteban V,
Tharinger H, et al. Beclin 1 and autophagy are required
for the tumorigenicity of breast cancer stem-like/pro-
genitor cells. Oncogene 2013; 32:2261-72, 1-11;
PMID:22733132; http://dx.doi.org/10.1038/onc.2012.
252
11. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC,
Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W,
Teng X, et al. Autophagy suppresses progression of K-
ras-induced lung tumors to oncocytomas and maintains
lipid homeostasis. Genes Dev 2013; 27:1447–61;
http://dx.doi.org/10.1101/gad.219642.113; PMID:
23824538
12. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM,
Chen GJ, Mathew R, McMahon M, White E. Autoph-
agy sustains mitochondrial glutamine metabolism and
growth of BrafV600E-driven lung tumors. Cancer Dis-
cov 2013; 3:1272–85; PMID:23965987; http://dx.doi.
org/10.1158/2159-8290.CD-13-0397
13. Huo Y, Cai H, Teplova I, Bowman-Colin C, Chen G,
Price S, Barnard N, Ganesan S, Karantza V, White E,
et al. Autophagy opposes p53-mediated tumor barrier
to facilitate tumorigenesis in a model of PALB2-associ-
ated hereditary breast cancer. Cancer Discov 2013;
3:894–907; http://dx.doi.org/10.1158/2159-8290.
CD-13-0011; PMID:23650262
14. Wei H, Wei S, Gan B, Peng X, Zou W, Guan JL.
Suppression of autophagy by FIP200 deletion inhibits
mammary tumorigenesis. Genes Dev 2011; 25:
1510–27; http://dx.doi.org/10.1101/gad.2051011;
PMID:21764854
15. Teplova I, Lozy F, Price S, Singh S, Barnard N, Cardiff
RD, Birge RB, Karantza V. ATG proteins mediate
efferocytosis and suppress inflammation in mammary
involution. Autophagy 2013; 9:459–75; http://dx.doi.
org/10.4161/auto.23164; PMID:23380905
16. Laddha SV, Ganesan S, Chan CS, White E. Mutational
landscape of the essential autophagy gene BECN1 in
human cancers. Mol Cancer Res 2014; 12:485–90;
PMID:24478461; http://dx.doi.org/10.1158/1541-
7786.MCR-13-0614
17. Kongara S, Kravchuk O, Teplova I, Lozy F, Schulte J,
Moore D, Barnard N, Neumann CA, White E, Kar-
antza V. Autophagy regulates keratin 8 homeostasis in
mammary epithelial cells and in breast tumors. Mol
Cancer Res 2010; 8:873–84; http://dx.doi.org/
10.1158/1541-7786.MCR-09-0494; PMID:20530580
18. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M,
Zhang X, Rowlands T, Egeblad M, Cowin P, Werb Z,
et al. Evidence that transgenes encoding components of
the Wnt signaling pathway preferentially induce mam-
mary cancers from progenitor cells. Proc Natl Acad Sci
U S A 2003; 100:15853–8; http://dx.doi.org/10.1073/
pnas.2136825100; PMID:14668450
19. Bu W, Chen J, Morrison GD, Huang S, Creighton CJ,
Huang J, Chamness GC, Hilsenbeck SG, Roop DR,
Leavitt AD, et al. Keratin 6a marks mammary bipoten-
tial progenitor cells that can give rise to a unique tumor
model resembling human normal-like breast cancer.
Oncogene 2011; 30:4399–409; http://dx.doi.org/
10.1038/onc.2011.147; PMID:21532625
20. Liu BY, McDermott SP, Khwaja SS, Alexander CM.
The transforming activity of Wnt effectors correlates
with their ability to induce the accumulation of mam-
mary progenitor cells. Proc Natl Acad Sci U S A 2004;
101:4158–63; http://dx.doi.org/10.1073/pnas.0400699101;
PMID:15020770
21. Grimm SL, Bu W, Longley MA, Roop DR, Li Y,
Rosen JM. Keratin 6 is not essential for mammary
gland development. Breast Cancer Res 2006; 8:R29;
PMID:16790075; http://dx.doi.org/10.1186/bcr1504
22. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth
GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader
JE. Generation of a functional mammary gland from a
single stem cell. Nature 2006; 439:84–8; http://dx.doi.
org/10.1038/nature04372; PMID:16397499
23. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant
F, Choi D, Li HI, Eaves CJ. Purification and unique
properties of mammary epithelial stem cells. Nature
2006; 439:993–7; http://dx.doi.org/10.1038/
nature04496; PMID:16395311
24. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest
NC, Lindeman GJ, Visvader JE. The mammary pro-
genitor marker CD61/beta3 integrin identifies cancer
stem cells in mouse models of mammary tumorigenesis.
Cancer Res 2008; 68:7711–7; http://dx.doi.org/
10.1158/0008-5472.CAN-08-1949; PMID:18829523
25. Dontu G, Abdallah WM, Foley JM, Jackson KW,
Clarke MF, Kawamura MJ, Wicha MS. In vitro propa-
gation and transcriptional profiling of human mam-
mary stem/progenitor cells. Genes Dev 2003;
17:1253–70; http://dx.doi.org/10.1101/gad.1061803;
PMID:12756227
26. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S,
Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama
Y, et al. Impairment of starvation-induced and consti-
tutive autophagy in Atg7-deficient mice. J Cell Biol
2005; 169:425–34; http://dx.doi.org/10.1083/
jcb.200412022; PMID:15866887
27. Jonkers J, Meuwissen R, van der Gulden H, Peterse H,
van der Valk M, Berns A. Synergistic tumor suppressor
activity of BRCA2 and p53 in a conditional mouse
model for breast cancer. Nat Genet 2001; 29:418–25;
http://dx.doi.org/10.1038/ng747; PMID:11694875
28. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA,
Mote PA, Clarke CL, Stingl J, Waterhouse PD, Kho-
kha R. Progesterone induces adult mammary stem cell
expansion. Nature 2010; 465:803–7; http://dx.doi.org/
10.1038/nature09091; PMID:20445538
29. Gonzalez-Suarez E, Branstetter D, Armstrong A, Dinh
H, Blumberg H, Dougall WC. RANK overexpression
in transgenic mice with mouse mammary tumor virus
promoter-controlled RANK increases proliferation and
impairs alveolar differentiation in the mammary epithe-
lia and disrupts lumen formation in cultured epithelial
acini. Mol Cell Biol 2007; 27:1442–54; http://dx.doi.
org/10.1128/MCB.01298-06; PMID:17145767
30. Fernandez-Valdivia R, Mukherjee A, Ying Y, Li J,
Paquet M, DeMayo FJ, Lydon JP. The RANKL signal-
ing axis is sufficient to elicit ductal side-branching and
alveologenesis in the mammary gland of the virgin
mouse. Dev Biol 2009; 328:127–39; http://dx.doi.org/
10.1016/j.ydbio.2009.01.019; PMID:19298785
31. Darnay BG, Ni J, Moore PA, Aggarwal BB. Activation
of NF-kappaB by RANK requires tumor necrosis factor
receptor-associated factor (TRAF) 6 and NF-kappaB-
inducing kinase. Identification of a novel TRAF6 inter-
action motif. J Biol Chem 1999; 274:7724–31; PMID:
10075662; http://dx.doi.org/10.1074/jbc.274.12.7724
32. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu
D, Simpson ER, Yasuda H, Smyth GK, Martin TJ,
Lindeman GJ, et al. Control of mammary stem cell
function by steroid hormone signalling. Nature 2010;
465:798–802; http://dx.doi.org/10.1038/nature09027;
PMID:20383121
33. Dougall WC. RANKL signaling in bone physiology
and cancer. Curr Opin Support Palliat Care 2007;
1:317–22; http://dx.doi.org/10.1097/SPC.0b013e3282f335be;
PMID:18685382
34. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roud-
ier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dou-
gall WC. RANK ligand mediates progestin-induced
mammary epithelial proliferation and carcinogenesis.
Nature 2010; 468:103–7; http://dx.doi.org/10.1038/
nature09495; PMID:20881963
www.landesbioscience.com 2051Autophagy
35. Lydon JP, DeMayo FJ, Conneely OM, O’Malley BW.
Reproductive phenotpes of the progesterone receptor
null mutant mouse. J Steroid Biochem Mol Biol 1996;
56:67–77; PMID:8603049; http://dx.doi.org/
10.1016/0960-0760(95)00254-5
36. Takayanagi H, Sato K, Takaoka A, Taniguchi T. Inter-
play between interferon and other cytokine systems in
bone metabolism. Immunol Rev 2005; 208:181–93;
http://dx.doi.org/10.1111/j.0105-2896.2005.00337.x;
PMID:16313349
37. Kongara S, Karantza V. The interplay between autoph-
agy and ROS in tumorigenesis. Front Oncol 2012;
2:171; PMID:23181220
38. Davie SA, Maglione JE, Manner CK, Young D, Cardiff
RD, MacLeod CL, Ellies LG. Effects of FVB/NJ and
C57Bl/6J strain backgrounds on mammary tumor phe-
notype in inducible nitric oxide synthase deficient
mice. Transgenic Res 2007; 16:193–201; http://dx.doi.
org/10.1007/s11248-006-9056-9; PMID:17206489
39. Visvader JE. Cells of origin in cancer. Nature 2011;
469:314–22; http://dx.doi.org/10.1038/nature09781;
PMID:21248838
40. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1
transgenic mice for studying the genetic basis of breast
cancer. Oncogene 2000; 19:1002–9; http://dx.doi.org/
10.1038/sj.onc.1203273; PMID:10713683
41. Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, Cai Y, Nor-
berg HV, Zhang T, Furuya T, et al. Beclin1 controls
the levels of p53 by regulating the deubiquitination
activity of USP10 and USP13. Cell 2011; 147:223–34;
http://dx.doi.org/10.1016/j.cell.2011.08.037;
PMID:21962518
42. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L,
Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H,
et al. A genomic predictor of response and survival fol-
lowing taxane-anthracycline chemotherapy for invasive
breast cancer. JAMA 2011; 305:1873–81; http://dx.
doi.org/10.1001/jama.2011.593; PMID:21558518
43. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni
B, Mamessier E, Tallet A, Chabannon C, Extra JM,
Jacquemier J, et al. A gene expression signature identi-
fies two prognostic subgroups of basal breast cancer.
Breast Cancer Res Treat 2011; 126:407–20; http://dx.
doi.org/10.1007/s10549-010-0897-9;
PMID:20490655
44. Shravage BV, Hill JH, Powers CM, Wu L, Baehrecke
EH. Atg6 is required for multiple vesicle trafficking
pathways and hematopoiesis in Drosophila. Develop-
ment 2013; 140:1321–9; http://dx.doi.org/10.1242/
dev.089490; PMID:23406899
45. Wang C, Liang CC, Bian ZC, Zhu Y, Guan JL.
FIP200 is required for maintenance and differentiation
of postnatal neural stem cells. Nat Neurosci 2013;
16:532–42; http://dx.doi.org/10.1038/nn.3365;
PMID:23542691
46. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisi-
lik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A,
Glimcher L, et al. Osteoclast differentiation factor
RANKL controls development of progestin-driven
mammary cancer. Nature 2010; 468:98–102; http://
dx.doi.org/10.1038/nature09387; PMID:20881962
47. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-
Ortega S, Urruticoechea A, Climent F, Soler MT,
Mu~noz P, Vi~nals F, et al. RANK induces epithelial-
mesenchymal transition and stemness in human mam-
mary epithelial cells and promotes tumorigenesis and
metastasis. Cancer Res 2012; 72:2879–88; http://dx.
doi.org/10.1158/0008-5472.CAN-12-0044;
PMID:22496457
48. K€uhn MC, Willenberg HS, Schott M, Papewalis C,
Stumpf U, Flohe S, Scherbaum WA, Schinner S. Adi-
pocyte-secreted factors increase osteoblast proliferation
and the OPG/RANKL ratio to influence osteoclast for-
mation. Mol Cell Endocrinol 2012; 349:180–8; http://
dx.doi.org/10.1016/j.mce.2011.10.018;
PMID:22040599
49. Bendre M, Gaddy D, Nicholas RW, Suva LJ. Breast
cancer metastasis to bone: it is not all about PTHrP.
Clin Orthop Relat Res 2003; (Suppl):S39–45; http://
dx.doi.org/10.1097/01.blo.0000093844.72468.f4;
PMID:14600591
50. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi
C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima
N. Autophagy-deficient mice develop multiple liver
tumors. Genes Dev 2011; 25:795–800; http://dx.doi.
org/10.1101/gad.2016211; PMID:21498569
51. Mari~no G, Salvador-Montoliu N, Fueyo A, Knecht E,
Mizushima N, Lopez-Otın C. Tissue-specific autoph-
agy alterations and increased tumorigenesis in mice
deficient in Atg4C/autophagin-3. J Biol Chem 2007;
282:18573–83; PMID:17442669; http://dx.doi.org/
10.1074/jbc.M701194200
52. Cook KL, Shajahan AN, Clarke R. Autophagy and
endocrine resistance in breast cancer. Expert Rev
Anticancer Ther 2011; 11:1283–94; http://dx.doi.org/
10.1586/era.11.111; PMID:21916582
53. Alexander CM, Goel S, Fakhraldeen SA, Kim S. Wnt
signaling in mammary glands: plastic cell fates and
combinatorial signaling. Cold Spring Harb Perspect
Biol 2012; 4: http://dx.doi.org/10.1101/cshperspect.
a008037; PMID:22661590
54. Bertrand FE, Angus CW, Partis WJ, Sigounas G.
Developmental pathways in colon cancer: crosstalk
between WNT, BMP, Hedgehog and Notch. Cell
Cycle 2012; 11:4344–51; http://dx.doi.org/10.4161/
cc.22134; PMID:23032367
55. Howe LR, Brown AM. Wnt signaling and breast
cancer. Cancer Biol Ther 2004; 3:36–41;
PMID:14739782; http://dx.doi.org/10.4161/cbt.3.1.561
56. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M,
Lambros MB, MacKay A, Natrajan R, Reis-Filho JS.
b-Catenin pathway activation in breast cancer is associ-
ated with triple-negative phenotype but not with
CTNNB1 mutation. Mod Pathol 2011; 24:209–31;
http://dx.doi.org/10.1038/modpathol.2010.205;
PMID:21076461
57. Alanazi MS, Parine NR, Shaik JP, Alabdulkarim HA,
Ajaj SA, Khan Z. Association of single nucleotide poly-
morphisms in Wnt signaling pathway genes with breast
cancer in Saudi patients. PLoS One 2013; 8:e59555;
http://dx.doi.org/10.1371/journal.pone.0059555;
PMID:23516639
58. Benhaj K, Akcali KC, Ozturk M. Redundant
expression of canonical Wnt ligands in human breast
cancer cell lines. Oncol Rep 2006; 15:701–7;
PMID:16465433
59. Goessl C, Katz L, Dougall WC, Kostenuik PJ, Zoog
HB, Braun A, Dansey R, Wagman RB. The develop-
ment of denosumab for the treatment of diseases of
bone loss and cancer-induced bone destruction. Ann N
Y Acad Sci 2012; 1263:29–40; http://dx.doi.org/
10.1111/j.1749-6632.2012.06674.x; PMID:22831177
60. Liu X, Holstege H, van der Gulden H, Treur-
Mulder M, Zevenhoven J, Velds A, Kerkhoven
RM, van Vliet MH, Wessels LF, Peterse JL, et al.
Somatic loss of BRCA1 and p53 in mice induces
mammary tumors with features of human BRCA1-
mutated basal-like breast cancer. Proc Natl Acad Sci
U S A 2007; 104:12111–6; http://dx.doi.org/
10.1073/pnas.0702969104; PMID:17626182
2052 Volume 10 Issue 11Autophagy
